CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia

Excessive microglial activation might be a central pathological process in GRN-related frontotemporal dementia (FTD-GRN). We measured soluble triggering receptor expressed on myeloid cells 2 (sTREM2), which is shed from disease-associated microglia following cleavage of TREM2, in cerebrospinal fluid...

Descripción completa

Detalles Bibliográficos
Autores: van der Ende, Emma L.|||0000-0003-2570-8796, Morenas-Rodríguez, Estrella|||0000-0002-7591-6051, McMillan, Corey T.|||0000-0002-7581-6405, Grossman, Murray|||0000-0002-7447-6218, Irwin, David J.|||0000-0002-5599-5098, Sanchez-Valle, Raquel|||0000-0001-7750-896X, Graff, Caroline|||0000-0002-9949-2951, Vandenberghe, Rik|||0000-0001-6237-2502, Pijnenburg, Yolande|||0000-0003-2464-1905, Laforce, Robert Jr|||0000-0002-2031-490X, Le Ber, Isabelle|||0000-0002-2508-5181, Lleó, Alberto|||0000-0002-2568-5478, Haass, Christian|||0000-0002-4869-1627, Suárez-Calvet, Marc|||0000-0002-2993-569X, van Swieten, John Cornelis, Seelaar, Harro|||0000-0003-1989-7527
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:271896
Acceso en línea:https://ddd.uab.cat/record/271896
https://dx.doi.org/urn:doi:10.1016/j.neurobiolaging.2021.02.024
Access Level:acceso abierto
Palabra clave:Frontotemporal dementia
Biomarker
Cerebrospinal fluid
Microglia
Strem2
Descripción
Sumario:Excessive microglial activation might be a central pathological process in GRN-related frontotemporal dementia (FTD-GRN). We measured soluble triggering receptor expressed on myeloid cells 2 (sTREM2), which is shed from disease-associated microglia following cleavage of TREM2, in cerebrospinal fluid of 34 presymptomatic and 35 symptomatic GRN mutation carriers, 6 presymptomatic and 32 symptomatic C9orf72 mutation carriers and 67 healthy noncarriers by ELISA. Although no group differences in sTREM2 levels were observed (GRN: symptomatic (median 5.2 ng/mL, interquartile range [3.9-9.2]) vs. presymptomatic (4.3 ng/mL [2.6-6.1]) vs. noncarriers (4.2 ng/mL [2.6-5.5]): p = 0.059; C9orf72: symptomatic (4.3 [2.9-7.0]) vs. presymptomatic (3.2 [2.2-4.2]) vs. noncarriers: p = 0.294), high levels were seen in a subset of GRN, but not C9orf72, mutation carriers, which might reflect differential TREM2-related microglial activation. Interestingly, 2 presymptomatic carriers with low sTREM2 levels developed symptoms after 1 year, whereas 2 with high levels became symptomatic after.

Similares en LA Referencia